Bifidobacterium animalis subsp. lactis BB-12 for Infant Colic
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Bifidobacterium animalis subsp. lactis BB-12 in Infant Colic grades Tier B — preliminary evidence. Effective, but with safety or population caveats.
B 🟡 B Preliminary Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.68
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
73%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.682
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Probiotics to prevent infantile colic
Finding: Across 6 RCTs (1886 infants) prophylactic probiotics did not reduce new colic cases (RR 0.46, 95% CI 0.18-1.19), though pooled daily crying time fell modestly (MD -32.57 min/day, 95% CI -55.60 to -9.54); all outcomes rated low-certainty (I2=93% for crying).
View on PubMed Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis
Finding: In 4 double-blind RCTs (345 infants) L. reuteri DSM 17938 cut day-21 crying/fussing by an adjusted -25.4 min/day (95% CI -47.3 to -3.5) and nearly doubled treatment success (IR 1.7, 95% CI 1.4-2.2; NNT 2.6 in breastfed infants), establishing L. reuteri (not BB-12) as the evidence-based first-line probiotic for breastfed colic.
View on PubMed Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review
Finding: Pooled probiotics reduced crying by an average -51 min/day (p=0.001), with the largest effect in exclusively breastfed infants (-74.28 min, p=0.0003) and the strongest single-strain signal for L. reuteri DSM 17938 (-64.66 min, p=0.03); BB-12 was only pooled at the species level and never quantified on its own.
View on PubMed The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12 in infant colic: A randomised, double blind, placebo-controlled trial
Finding: In 80 exclusively breastfed infants (40/group), 80% of the BB-12 group vs 32.5% of placebo achieved a >=50% reduction in daily crying at 28 days (P<0.0001), with greater drops in crying episodes (-4.7 vs -2.3, P<0.05) and concordant gut-microbiota/immune-marker shifts.
View on PubMed Efficacy of Bifidobacterium animalis subsp. lactis, BB-12 on infant colic - a randomised, double-blinded, placebo-controlled study
Finding: In 192 full-term breastfed infants, the share achieving >=50% reduction in daily crying/fussing at 21 days was significantly higher with BB-12 (P<0.001), with fewer crying episodes (to 5.0 vs 7.5, P<0.001) and longer daily sleep (+60.7 vs +31.9 min, P<0.001).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… source↗
L5a NIH Office of Dietary Supplements
Supportive
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … source↗
L5b Mayo Clinic
Cautious
One factor that may add to colic is that the good bacteria in an infant's gut is out of balance, and one treatment being studied is the use of good bacteria, called probiotics. Probiotics might help the bacterial balance to improve overall gut health. Some studies have shown less crying time when babies with colic were treated with a bacterium called Lactobacillus reuteri. However, the studies … source↗
L5e Specialty Society (condition-mapped)
Supportive
Healthcare providers may recommend B lactis BB-12 (at least 10^8 CFU/day, for 21-28 days) for the management of infant colic in breastfed infants. source↗